M. Amabile

M. Baccarani, G. Rosti, G. Martinelli, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

M. Baccarani, G. Rosti, G. Martinelli, 2010, Haematologica.

Achieving aMajor Molecular Response at theTime of a Complete Cytogenetic Response ( CCgR ) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

M. Baccarani, S. Paolini, G. Rosti, 2006 .

Thyrosin kinase inhibitors: nilotinib

M. Baccarani, G. Martinelli, S. Soverini, 2009 .

A randomized study of interferon- a versus interferon- a and low-dose arabinosyl cytosine in chronic myeloid leukemia

M. Baccarani, G. Rosti, G. Martinelli, 2002 .

Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial

M. Baccarani, G. Rosti, G. Martinelli, 2010 .

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

M. Baccarani, G. Rosti, G. Martinelli, 2009, Haematologica.

Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

R. Fanin, M. Baccarani, G. Martinelli, 2007, Bone Marrow Transplantation.

Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.

M. Baccarani, G. Rosti, G. Martinelli, 2005 .

Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.

M. Baccarani, G. Rosti, G. Martinelli, 2009 .

Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia

P. Piccaluga, G. Martinelli, S. Tura, 2000, Leukemia.

Interleukin‐11 (IL‐11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells

S. Ferrari, G. Martinelli, S. Tura, 1995, British journal of haematology.

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl‐positive acute lymphoid leukaemia

M. Baccarani, P. Piccaluga, M. Rondoni, 2004, European journal of haematology.

Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.

M. Baccarani, P. Tazzari, F. Ricci, 2006, Experimental hematology.

Abductor muscle strengthening in THA patients operated with minimally-invasive anterolateral approach for developmental hip dysplasia

M. Benedetti, F. Taddei, E. Vaienti, 2019, Hip international : the journal of clinical and experimental research on hip pathology and therapy.

Interleukin‐4 Downregulates Nuclear Factor‐Erythroid 2 (NF‐E2) Expression in Primary Megakaryocytes and in Megakaryoblastic Cell Lines

G. Martinelli, S. Tura, N. Vianelli, 2001, Stem cells.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

M. Baccarani, G. Rosti, G. Martinelli, 2004, Blood.

Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy

M. Baccarani, G. Martinelli, G. Saglio, 2000, Bone Marrow Transplantation.

Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.

G. Martinelli, G. Saglio, E. Ottaviani, 2000, Haematologica.

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

M. Baccarani, P. Piccaluga, M. Rondoni, 2003, Clinical chemistry.

Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)

G. Martinelli, G. Saglio, E. Ottaviani, 1999, Leukemia.

Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient

M. Baccarani, G. Martinelli, G. Saglio, 1999, Leukemia.

leukemia patients reaction" for the detection of BCR/ABL transcript in chronic myeloid A new method of "in-cell reverse transcriptase-polymerase chain

G. Martinelli, N. Testoni, P. Farabegoli, 2011 .

A new method of "in-cell reverse transcriptase-polymerase chain reaction" for the detection of BCR/ABL transcript in chronic myeloid leukemia patients.

G. Martinelli, S. Tura, N. Testoni, 1996, Blood.

Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.

R. Fanin, M. Baccarani, G. Rosti, 2004 .

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

M. Baccarani, A. Neri, G. Martinelli, 2003, Blood.

Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.

M. Baccarani, P. Piccaluga, G. Martinelli, 2002, Blood.

Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.

M. Baccarani, G. Rosti, G. Martinelli, 2002, Haematologica.

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.

Sante Tura, Giovanni Martinelli, Giuseppe Saglio, 2002, Blood.

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.

R. Foà, M. Baccarani, S. Chiaretti, 2008, Blood.

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

M. Baccarani, G. Rosti, G. Martinelli, 2011, Blood.

Detection of clonality by heteroduplex analysis of amplified junctional region of T-cell receptor gamma in patients with T-cell acute lymphoblastic leukemias.

G. Martinelli, S. Tura, N. Testoni, 1997, Haematologica.

Amplification of third-complementary-determining-region (CDR-III) of heavy chain immunoglobulin gene (IgH) in one hundred adult acute leukemias.

G. Martinelli, S. Tura, N. Testoni, 1997, Leukemia & lymphoma.

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

M. Baccarani, G. Rosti, G. Martinelli, 2006, Clinical Cancer Research.

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

R. Foà, M. Baccarani, A. Vitale, 2011, Haematologica.

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.

M. Baccarani, G. Rosti, G. Martinelli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.

G. Martinelli, R. Conte, S. Tura, 1996, Blood.

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

M. Baccarani, G. Rosti, G. Martinelli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients

M. Baccarani, P. Piccaluga, M. Rondoni, 2008, Leukemia.

Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.

G. Martinelli, E. Ottaviani, S. Tura, 1999, Haematologica.

Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response

G. Rosti, G. Martinelli, E. Ottaviani, 2000, Leukemia & lymphoma.

Interleukin-9 stimulates the proliferation of human myeloid leukemic cells.

S. Ferrari, G. Martinelli, M. R. Ricciardi, 1996, Blood.

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.

G. Martinelli, E. Ottaviani, E. Zamagni, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

R. Fanin, M. Baccarani, P. Piccaluga, 2005, Blood.

Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.

G. Martinelli, E. Ottaviani, E. Zamagni, 2000, Haematologica.

A case of coexistence between JAK2V617F and BCR /ABL

G. Rosti, E. Ottaviani, C. Fozza, 2008, European journal of haematology.

Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.

G. Martinelli, G. Saglio, E. Ottaviani, 1998, Haematologica.

Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib.

S. Pileri, M. Cazzola, M. Gobbi, 2004 .

Molecular R emission A fter A llogeneic o r A utologous Transplantation o f H ematopoietic S tem C ells f or Multiple M yeloma

G. Martinelli, E. Ottaviani, E. Zamagni, 2000 .

Ischemia-Modified Albumin Expression: Is there a Difference between Male and Female Subjects?

S. Stea, A. Toni, A. Beraudi, 2019, Clinical laboratory.

cells Interleukin-9 stimulates the proliferation of human myeloid leukemic

S. Ferrari, G. Martinelli, A. Tafuri, 2011 .

Interleukin-9 in human myeloid leukemia cells.

S. Ferrari, G. Martinelli, A. Tafuri, 1997, Leukemia & lymphoma.

An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia.

G. Martinelli, A. Tabilio, S. Tura, 1999, Haematologica.

FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.

P. Zinzani, G. Martinelli, S. Tura, 1996, Leukemia & lymphoma.

A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon

A. Tabilio, F. Forconi, F. Lauria, 2003 .

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

M. Baccarani, G. Rosti, G. Martinelli, 2009 .

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

M. Baccarani, M. Rondoni, S. Paolini, 2008 .

A Prospective Study in Ph+ Chronic Myeloid Leukemia (CML) Patients Showing That Interphase Fluorescence in Situ Hybridization (FISH) Is Effective as Conventional Cytogenetics for Definition of Cytogenetic Response. Correlation with Molecular Response (by the GIMEMA CML WP).

M. Mancini, M. Baccarani, C. Mecucci, 2006 .

leukemia Molecular response to Imatinib in late chronic phase chronic myeloid

M. Baccarani, G. Rosti, G. Martinelli, 2012 .

Metal-on-metal hip prostheses: Correlation between debris in the synovial fluid and levels of cobalt and chromium ions in the bloodstream

P. Apostoli, S. Stea, B. Bordini, 2014, International Orthopaedics.

ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.

M. Baccarani, G. Rosti, G. Martinelli, 2004 .

Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: protocol for a prospective cohort study

S. Zaffagnini, P. Rucci, B. Bordini, 2019, BMC Musculoskeletal Disorders.

Molecular analysis of PML‐RARa fusion mRNA detected by reverse transcription‐polymerase chain reaction assay in long‐term disease‐free acute promyelocytic leukaemia patients

G. Martinelli, S. Tura, D. Russo, 1995, British journal of haematology.

Squeaking and other noises in patients with ceramic-on-ceramic total hip arthroplasty

S. Stea, B. Bordini, A. Toni, 2020, Hip international : the journal of clinical and experimental research on hip pathology and therapy.

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.

M. Baccarani, G. Martinelli, A. Martelli, 2005 .

A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.

C. Taccioli, M. Baccarani, G. Rosti, 2004 .

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.

M. Baccarani, P. Piccaluga, M. Rondoni, 2004, Haematologica.

Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty

S. Zaffagnini, P. Rucci, B. Bordini, 2023, BMC Musculoskeletal Disorders.

Hematologic, cytogenetic and molecular response to Glivec (STI571) in Ph+ chronic myeloid leukemia (CML) in accelerated and blastic phase: a prospective study of the Italian cooperative study group on CML

M. Baccarani, G. Martinelli, D. Cilloni, 2001 .

Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months

M. Baccarani, G. Rosti, G. Martinelli, 2010 .

CML WP the definition of complete cytogenetic response: a study of the GIMEMA for fluorescence in situ hybridization and chromosome banding analysis Chronic myeloid leukemia: a prospective comparison of interphase

M. Baccarani, G. Rosti, A. Cuneo, 2013 .

Chronic Myeloid Leukemia (CML) Patients with “Suboptimal” Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to “Optimal” Responders: A GIMEMA CML WORKING PARTY Analysis.

M. Baccarani, G. Rosti, G. Martinelli, 2009 .

bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use

M. Baccarani, A. Neri, G. Martinelli, 2002 .

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.

R. Foà, M. Baccarani, S. Chiaretti, 2008, Blood.

M. Baccarani, S. Paolini, G. Rosti, 2009, Blood.

Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.

M. Baccarani, G. Martinelli, G. Saglio, 2001, Haematologica.

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

M. Baccarani, M. Vignetti, G. Gaidano, 2009 .

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

M. Baccarani, G. Rosti, G. Martinelli, 2007 .

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

P. Galieni, M. Baccarani, G. Rosti, 2009, Blood.

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.

M. Baccarani, G. Rosti, G. Martinelli, 2004, Blood.